NOSEVAC - European commission

Date: 2023-2028

Funding: Commission européeenne

Coordinator: Delphine Grynberg

SAVOIR - Social Sciences and Humanities Research Council of Canada (SSHRC)

Date: 2023-2027

Funding: Social Sciences and Humanities Research Council of Canada (SSHRC)

Coordinator: Amélie M. Achim

Partner in lab: Dominique Knutsen

CAPES COFECUB

Date: 2023-2026

Funding: CAPES - COFECUB (Comité Français d'Evaluation de la Coopréation Universitaire et Scientifique avec le Brésil)

Coordinator: Cédrick Bonnet

PHC Aurora

Date: 2023-2025

Funding: PHC Aurora - Campus France

Coordinator: Bilge Sayim & Pr Jonas R. Kunst, University of Oslo

PHC Bosphore

Date: 2023-2025

Funding: PHC BOSPHORE - Campus France

Coordinator: Bilge Sayim

"Information compression by the visual brain and the neural signature of redundancy masking" with Sabanci University, Istanbul

Mobility grant USA

2023/2024: Grant obtained by Solène Kalénine

CAPES (Brasil)

Date: 2023-2024

Funding: CAPES (Brésil)

Coordinator in lab: Cédrick Bonnet

Coordinator in Brasil: Dr. Caio Cruz

CHAIR FRANCO-BRESILIENNE

Date: 2023

Funding: 3 universités brésiliennes (USP, UNESP, UNICAMP) et le Consulat Général de France à Sao Paulo

Coordinator: Cédrick Bonnet

PHC Germaine de Stael

Date: 2022-2023

Funding: PHC Germaine de Stael - Campus France

Coordinator in SCALab: Dominique Knutsen

Porteur de projet Suisse: M. Fossard

FAIR

Date: 2021-2024

Funding: H2020

Partners in lab: Delphine Grynberg et Christelle Duprez

Abstract:
Bacterial pneumonia is a leading cause of morbidity and mortality worldwide. Antibiotics constitute the standard of care but are faced with the emergence of antimicrobial resistance (AMR) and the curative failure. The FAIR consortium aims at assessing an adjunct to antibiotic therapy as an emerging concept of overcome AMR in pneumonia. The project leverages (i) a unique immunomodulatory flagellin that enhances airway epithelial innate immune defences and increases the therapeutic outcome relative to antibiotic alone, and (ii) airway-specific aerosol delivery by nebulization.
FAIR’s objectives are to:
• develop nebulization modalities for optimal airway targeting and rapid action at the infection site
• demonstrate that nebulized flagellin strengthens the response to antibiotics in relevant preclinical models of antibioticresistant pneumonia
• identify host immune factors required for the gain of protection with systems biology
• implement pharmacokinetics/pharmacodynamics model-based design and simulation for clinical validation
• assess nebulized flagellin’s safety in a Phase I clinical trial.
• analyze the acceptability and economic relevance of the therapy
• identify stratification markers that predict the course of pneumonia and treatment in antibiotic-treated cohorts.
Expected outcomes include the enrichment of the pipeline of novel treatments against pneumonia, reinforcement of EU capacity to control AMR and infections, the Phase I safety report on nebulized flagellin, recommendations for future trials, and acceptability by the stakeholders and cost-effectiveness for public health. FAIR will develop new avenues of research on mechanisms of action of the adjunct flagellin, and will define (for future trials) the subpopulation of patients that might benefit most from this treatment. Our industrial partnerships and exploitation plan will enable straightforward development of drug and nebuliser device, and bring innovation to the patients.

VISOSCIL- Basque Center on Cognition, Brain and Language

Date: 2021-2022

Funding: Basque Center on Cognition, Brain and Language

Coordinator: Gwendoline Mahé

Maimonide

Date: 2021-2022

Funding: PHC Maimonide, Campus France

Coordinator: Yann Coello

Team:
France : Mme Bartolo Angela*, Professeur
M. Coello Yann*, Professeur
M. To be recruited To be recruited*, PhD
Israël : M. Fishbain Barak*, Assistant professor
Mme Givon-Benjo Nur*, Phd
Mme Okon-Singer Hadas*, Associated professor

MONUMENT

Date: 2020-2023

Funding: Interreg 2 Seas Mers Zeeën

Partners in lab: Emilie Wawrziczny et Pascal Antoine

More informations...

CASCADE

Date: 2017-2021

Funding: Interreg 2 Mers

Partners: Pascal Antoine et Mohamad El Haj (University of Nantes)

More information...